PTC Therapeutics | PTCT - Net Income


PTC Therapeutics reported $-134.96M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 71.78M 45.11M Sep/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
Amgen USD 1.33B 1.88B Dec/2025
BioCryst Pharmaceuticals USD -88.88M 74.85M Dec/2024
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Cytokinetics USD -306.18M 171.81M Sep/2025
Daiichi Sankyo JPY 86.63B 41.32B Dec/2025
Enanta Pharmaceuticals USD -22.29M 93.76M Dec/2024
Esperion Therapeutics USD -29.52M 32.4M Sep/2024
Gilead Sciences USD 2.18B 869M Dec/2025
Incyte USD 299.28M 124.89M Dec/2025
Ionis Pharmaceuticals USD -128.61M 252.16M Sep/2025
Ironwood Pharmaceuticals USD 3.19M 457K Dec/2024
Karyopharm Therapeutics USD -30.78M 1.29M Dec/2024
Novartis USD 3.93B 96M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
PTC Therapeutics USD -134.96M 150.86M Dec/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Roche Holding CHF 5.47B 1.76B Dec/2025
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sarepta Therapeutics USD -179.95M 376.84M Sep/2025
TG Therapeutics USD 390.9M 362.71M Sep/2025
Ultragenyx Pharmaceutical USD -129M 51.41M Dec/2025
Vertex Pharmaceuticals USD 1.19B 108.2M Dec/2025
Xencor USD -6.03M 24.8M Sep/2025